NK cell-based Immunotherapy for Acute Myeloid Leukemia: An Exciting Future
Keywords:
NK-cell, Immunotherapy, Acute myeloid leukemiaAbstract
Given that allogeneic hematopoietic transplantation has been achieved in the treatment of acute myeloid leukemia (AML) over the past decade by providing graft-versus leukemia effect. However, age at diagnosis, donor availability, the treatment-related toxicities of allogeneic hematopoietic cell transplantation, relapse/refractory disease and minimal residual disease (MRD) prior to transplantation remain major problems. Novel approaches in cellular immunotherapy have contributed to substantial improvement in the treatment of hematologic malignancies, while adoptive NK cells therapy has also emerged as a promising treatment option, to improve survival in AML patients in the context of transplantation and nontransplantation. In this review, we summarize biology of NK cells and current different strategies of adoptive NK therapy for treating AML in clinical studies, also discuss about future directions of NK cell-based immunotherapy for the treatment of AML.
References
Döhner H, Weisdorf DJ, Bloomfield CD. Acute Myeloid Leukemia. Longo DL, editor. N Engl J Med. 2015;373 (12): 1136–52.
Terwilliger T, Abdul-Hay M. Acute lymphoblastic leukemia: a comprehensive review and 2017 update. Blood Cancer J. 2017 Jun;7(6): e577–e577.
Löwenberg B, Downing JR, Burnett A. Acute myeloid leukemia. N Engl J Med. 1999 ;341 (14): 1051–62.
Roussel X, Daguindau E, Berceanu A, Desbrosses Y, Warda W, Neto da Rocha M, et al. Acute Myeloid Leukemia: From Biology to Clinical Practices Through Development and Pre-Clinical Therapeutics. Front Oncol. 2020 Dec 9; 10: 599933.
Blum WG, Mims AS. Treating acute myeloid leukemia in the modern era: A primer. Cancer. 2020; 126 (21): 4668–77.
Estey E, Karp JE, Emadi A, Othus M, Gale RP. Recent drug approvals for newly diagnosed acute myeloid leukemia: gifts or a Trojan horse? Leukemia. 2020; 34 (3): 671–81.
Schuurhuis GJ, Heuser M, Freeman S, Béné M-C, Buccisano F, Cloos J, et al. Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party. Blood. 2018; 131 (12): 1275–91.
Grimwade D, Freeman SD. Defining minimal residual disease in acute myeloid leukemia: which platforms are ready for “prime time”? Blood. 2014 ;124 (23): 3345–55.
Terwijn M, van Putten WLJ, Kelder A, van der Velden VHJ, Brooimans RA, Pabst T, et al. High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study. J Clin Oncol Off J Am Soc Clin Oncol. 2013; 31 (31): 3889–97.
Araki D, Wood BL, Othus M, Radich JP, Halpern AB, Zhou Y, et al. Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia: Time to Move Toward a Minimal Residual Disease-Based Definition of Complete Remission? J Clin Oncol 2016; 34 (4): 329–36.
Ball B, Stein EM. Which are the most promising targets for minimal residual disease-directed therapy in acute myeloid leukemia prior to allogeneic stem cell transplant? Haematologica. 2019; 104 (8): 1521–31.
Davis ZB, Felices M, Verneris MR, Miller JS. Natural Killer Cell Adoptive Transfer Therapy: Exploiting the First Line of Defense Against Cancer. Cancer J Sudbury Mass. 2015; 21 (6): 486–91.
Rezvani K, Rouce R, Liu E, Shpall E. Engineering Natural Killer Cells for Cancer Immunotherapy. Mol Ther J Am Soc Gene Ther. 2017; 25 (8): 1769–81.
Nair S, Dhodapkar MV. Natural Killer T Cells in Cancer Immunotherapy. Front Immunol. 2017; 8 :1178.
Locatelli F, Moretta F, Brescia L, Merli P. Natural killer cells in the treatment of high-risk acute leukaemia. Semin Immunol. 2014; 26 (2): 173–9.
Handgretinger R, Lang P, André MC. Exploitation of natural killer cells for the treatment of acute leukemia. Blood. 2016; 127 (26): 3341–9.
Koehl U, Kalberer C, Spanholtz J, Lee DA, Miller JS, Cooley S, et al. Advances in clinical NK cell studies: Donor selection, manufacturing and quality control. Oncoimmunology. 2016; 5 (4): e1115178.
Cooley S, Parham P, Miller JS. Strategies to activate NK cells to prevent relapse and induce remission following hematopoietic stem cell transplantation. Blood. 2018 ;131 (10):1053–62.
Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science. 2002; 295 (5562): 2097–100.
Childs RW, Carlsten M. Therapeutic approaches to enhance natural killer cell cytotoxicity against cancer: the force awakens. Nat Rev Drug Discov. 2015;14 (7): 487–98.
Kottaridis PD, North J, Tsirogianni M, Marden C, Samuel ER, Jide-Banwo S, et al. Two-Stage Priming of Allogeneic Natural Killer Cells for the Treatment of Patients with Acute Myeloid Leukemia: A Phase I Trial. PloS One. 2015; 10 (6): e0123416.
Rubnitz JE, Inaba H, Ribeiro RC, Pounds S, Rooney B, Bell T, et al. NKAML: A Pilot Study to Determine the Safety and Feasibility of Haploidentical Natural Killer Cell Transplantation in Childhood Acute Myeloid Leukemia. J Clin Oncol. 2010; 28 (6): 955–9.
Romee R, Rosario M, Berrien-Elliott MM, Wagner JA, Jewell BA, Schappe T, et al. Cytokine-induced memorylike natural killer cells exhibit enhanced responses against myeloid leukemia. Sci Transl Med. 2016; 8 (357): 357ra123-357ra123.
Miller JS, Soignier Y, PanoskaltsisMortari A, McNearney SA, Yun GH, Fautsch SK, et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood. 2005; 105 (8):3051–7.
Fehniger TA, Miller JS, Stuart RK, Cooley S, Salhotra A, Curtsinger J, et al. A Phase 1 Trial of CNDO-109- Activated Natural Killer Cells in Patients with High-Risk Acute Myeloid Leukemia. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant. 2018; 24(8):1581–9.
Björklund AT, Carlsten M, Sohlberg E, Liu LL, Clancy T, Karimi M, et al. Complete Remission with Reduction of High-Risk Clones following Haploidentical NK-Cell Therapy against MDS and AML. Clin Cancer Res. 2018; 24 (8):1834–44.
Ciurea SO, Schafer JR, Bassett R, Denman CJ, Cao K, Willis D, et al. Phase 1 clinical trial using mbIL 21 ex vivo–expanded donor-derived NK cells after haploidentical transplantation. Blood. 2017;130 (16):1857–68.
Wang Y, Bo J, Dai H, Lu X, Lv H, Yang B, et al. CIK cells from recurrent or refractory AML patients can be efficiently expanded in vitro and used for reduction of leukemic blasts in vivo. Exp Hematol. 2013; 41(3): 241-252. e3.
Vela M, Corral D, Carrasco P, Fernández L, Valentín J, González B, et al. Haploidentical IL-15/41BBL activated and expanded natural killer cell infusion therapy after salvage chemotherapy in children with relapsed and refractory leukemia. Cancer Lett. 2018; 422: 107–17.
Bachanova V, Cooley S, Defor TE, Verneris MR, Zhang B, McKenna DH, et al. Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein. Blood. 2014; 123 (25): 3855–63.
Daher M, Melo Garcia L, Li Y, Rezvani K. CAR-NK cells: the next wave of cellular therapy for cancer. Clin Transl Immunol [Internet]. 2021;10 (4). Available from: https://onlinelibrary.wiley.com/doi/10.1002/cti2.1274
Davis ZB, Vallera DA, Miller JS, Felices M. Natural killer cells unleashed: Checkpoint receptor blockade and BiKE/TriKE utilization in NK-mediated anti-tumor immunotherapy. Semin Immunol. 2017; 31: 64–75.
Golán I, Rodríguez de la Fuente L, Costoya J. NK Cell-Based Glioblastoma Immunotherapy. Cancers. 2018; 10 (12): 522.
Liu X, Li L, Si F, Huang L, Zhao Y, Zhang C, Hoft DF, Peng G. NK and NKT cells have distinct properties and functions in cancer. Oncogene. 2021; 40 (27): 4521-4537
Pahl J, Cerwenka A. Tricking the balance: NK cells in anti-cancer immunity. Immunobiology. 2017; 222 (1):11–20.
Morvan MG, Lanier LL. NK cells and cancer: you can teach innate cells new tricks. Nat Rev Cancer. 2016; 16 (1): 7–19.
Vallera DA, Ferrone S, Kodal B, Hinderlie P, Bendzick L, Ettestad B, et al. NK-Cell-Mediated Targeting of Various Solid Tumors Using a B7-H3 Tri-Specific Killer Engager In Vitro and In Vivo. Cancers. 2020; 12 (9): 2659.
Lorenzo-Herrero S, López-Soto A, Sordo-Bahamonde C, GonzalezRodriguez A, Vitale M, Gonzalez S. NK Cell-Based Immunotherapy in Cancer Metastasis. Cancers. 2018; 11 (1): 29.
Sun JC, Lanier LL. NK cell development, homeostasis and function: parallels with CD8+ T cells. Nat Rev Immunol. 2011; 11 (10): 645–57.
Lundqvist A, Berg M, Smith A, Childs RW. Bortezomib Treatment to Potentiate the Anti-tumor Immunity of Ex-vivo Expanded Adoptively Infused Autologous Natural Killer Cells. J Cancer. 2011; 2: 383–5.
Lundqvist A, Yokoyama H, Smith A, Berg M, Childs R. Bortezomib treatment and regulatory T-cell depletion enhance the antitumor effects of adoptively infused NK cells. Blood. 2009; 113 (24): 6120–7.
Geiger TL, Sun JC. Development and maturation of natural killer cells. Curr Opin Immunol. 2016; 39: 82–9.
Shimasaki N, Jain A, Campana D. NK cells for cancer immunotherapy. Nat Rev Drug Discov. 2020; 19 (3): 200–18.
Fionda C, Soriani A, Zingoni A, Santoni A, Cippitelli M. NKG2D and DNAM-1 Ligands: Molecular Targets for NK Cell-Mediated Immunotherapeutic Intervention in Multiple Myeloma. BioMed Res Int. 2015; 2015:1–9.
Ochoa MC, Minute L, Rodriguez I, Garasa S, Perez-Ruiz E, Inogés S, et al. Antibody-dependent cell cytotoxicity: immunotherapy strategies enhancing effector NK cells. Immunol Cell Biol. 2017; 95 (4): 347–55.
Böttcher JP, Bonavita E, Chakravarty P, Blees H, Cabeza-Cabrerizo M, Sammicheli S, et al. NK Cells Stimulate Recruitment of cDC1 into the Tumor Microenvironment Promoting Cancer Immune Control. Cell. 2018; 172 (5):1022-1037.e14.
Barry KC, Hsu J, Broz ML, Cueto FJ, Binnewies M, Combes AJ, et al. A natural killer-dendritic cell axis defines checkpoint therapy-responsive tumor microenvironments. Nat Med. 2018; 24 (8): 1178–91.
Curti A, Ruggeri L, D’Addio A, Bontadini A, Dan E, Motta MR, et al. Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients. Blood. 2011; 118 (12): 3273–9.
Thielens A, Vivier E, Romagné F. NK cell MHC class I specific receptors (KIR): from biology to clinical intervention. Curr Opin Immunol. 2012; 24 (2): 239–45.
Mahaweni NM, Ehlers FAI, Bos GMJ, Wieten L. Tuning Natural Killer Cell Anti-Multiple Myeloma Reactivity by Targeting Inhibitory Signaling via KIR and NKG2A. Front Immunol. 2018; 4; 9: 2848.
Asai O, Longo DL, Tian ZG, Hornung RL, Taub DD, Ruscetti FW, et al. Suppression of graft-versus-host disease and amplification of graftversus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation. J Clin Invest. 1998 ;101 (9): 1835–42.
Barrett AJ. Understanding and harnessing the graft-versus-leukaemia effect. Br J Haematol. 2008; 142 (6): 877–88.
Krakow EF, Bergeron J, Lachance S, Roy D-C, Delisle J-S. Harnessing the power of alloreactivity without triggering graft-versus-host disease: how non-engrafting alloreactive cellular therapy might change the landscape of acute myeloid leukemia treatment. Blood Rev. 2014; 28 (6): 249–61.
Wanquet A, Bramanti S, Harbi S, Fürst S, Legrand F, Faucher C, et al. Killer Cell Immunoglobulin-Like ReceptorLigand Mismatch in Donor versus Recipient Direction Provides Better Graft-versus-Tumor Effect in Patients with Hematologic Malignancies Undergoing Allogeneic T Cell-Replete Haploidentical Transplantation Followed by Post-Transplant Cyclophosphamide. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant. 2018; 24 (3): 549–54.
Weisdorf D, Cooley S, Wang T, Trachtenberg E, Vierra-Green C, Spellman S, et al. KIR B donors improve the outcome for AML patients given reduced intensity conditioning and unrelated donor transplantation. Blood Adv. 2020;4 (4) :740–54.
Myers JA, Miller JS. Exploring the NK cell platform for cancer immunotherapy. Nat Rev Clin Oncol. 2021; 18 (2): 85–100.
Sandoval-Borrego D, Moreno-Lafont MC, Vazquez-Sanchez EA, GutierrezHoya A, López-Santiago R, MontielCervantes LA, et al. Overexpression of CD158 and NKG2A Inhibitory Receptors and Underexpression of NKG2D and NKp46 Activating Receptors on NK Cells in Acute Myeloid Leukemia. Arch Med Res. 2016; 47 (1): 55–64.
Lazarova M, Steinle A. The NKG2D axis: an emerging target in cancer immunotherapy. Expert Opin Ther Targets. 2019; 23 (4): 281–94.
Damele L, Ottonello S, Mingari MC, Pietra G, Vitale C. Targeted Therapies: Friends or Foes for Patient’s NK Cell-Mediated Tumor ImmuneSurveillance? Cancers. 2020 ; 12 (4): E774.
Coles SJ, Hills RK, Wang ECY, Burnett AK, Man S, Darley RL, et al. Expression of CD200 on AML blasts directly suppresses memory T-cell function. Leukemia. 2012; 26 (9): 2148–51.
Nowbakht P, Ionescu M-CS, Rohner A, Kalberer CP, Rossy E, Mori L, et al. Ligands for natural killer cell-activating receptors are expressed upon the maturation of normal myelomonocytic cells but at low levels in acute myeloid leukemias. Blood. 2005 1; 105(9): 3615–22.
Kearney CJ, Ramsbottom KM, Voskoboinik I, Darcy PK, Oliaro J. Loss of DNAM-1 ligand expression by acute myeloid leukemia cells renders them resistant to NK cell killing. Oncoimmunology. 2016; 5 (8): e1196308.
Baragaño Raneros A, Martín-Palanco V, Fernandez AF, Rodriguez RM, Fraga MF, Lopez-Larrea C, et al. Methylation of NKG2D ligands contributes to immune system evasion in acute myeloid leukemia. Genes Immun. 2015; 16 (1): 71–82.
Salih HR, Antropius H, Gieseke F, Lutz SZ, Kanz L, Rammensee H-G, et al. Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia. Blood. 2003; 102 (4): 1389–96.
Yang H, Bueso-Ramos C, DiNardo C, Estecio MR, Davanlou M, Geng Q-R, et al. Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents. Leukemia. 2014; 28 (6):1280–8.
Cekic C, Day Y-J, Sag D, Linden J. Myeloid expression of adenosine A2A receptor suppresses T and NK cell responses in the solid tumor microenvironment. Cancer Res. 2014; 74 (24): 7250–9.
Trzonkowski P, Szmit E, Myśliwska J, Dobyszuk A, Myśliwski A. CD4+ CD25+ T regulatory cells inhibit cytotoxic activity of T CD8+ and NK lymphocytes in the direct cell-to-cell interaction. Clin Immunol Orlando Fla. 2004; 112 (3): 258–67.
Castriconi R, Cantoni C, Della Chiesa M, Vitale M, Marcenaro E, Conte R, et al. Transforming growth factor beta 1 inhibits expression of NKp30 and NKG2D receptors: consequences for the NK-mediated killing of dendritic cells. Proc Natl Acad Sci U S A. 2003; 100 (7): 4120–5.
Hasmim M, Messai Y, Ziani L, Thiery J, Bouhris J-H, Noman MZ, et al. Critical Role of Tumor Microenvironment in Shaping NK Cell Functions: Implication of Hypoxic Stress. Front Immunol. 2015; 6: 482.
Ogonek J, Kralj Juric M, Ghimire S, Varanasi PR, Holler E, Greinix H, et al. Immune Reconstitution after Allogeneic Hematopoietic Stem Cell Transplantation. Front Immunol [Internet]. 2016;7. Available from: http://journal.frontiersin.org/article/10.3389/fimmu.2016.00507/full
Kanda J, Chiou L-W, Szabolcs P, Sempowski GD, Rizzieri DA, Long GD, et al. Immune Recovery in Adult Patients after Myeloablative Dual Umbilical Cord Blood, Matched Sibling, and Matched Unrelated Donor Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2012; 18 (11): 1664-1676.e1.
Chang Y-J, Zhao X-Y, Huang X-J. Immune Reconstitution after Haploidentical Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2014; 20 (4): 440–9.
Storek J, Dawson MA, Storer B, Stevens-Ayers T, Maloney DG, Marr KA, et al. Immune reconstitution after allogeneic marrow transplantation compared with blood stem cell transplantation. Blood. 2001; 97 (11): 3380–9.
Passweg JR, Tichelli A, Meyer-Monard S, Heim D, Stern M, Kühne T, et al. Purified donor NK-lymphocyte infusion to consolidate engraftment after haploidentical stem cell transplantation. Leukemia. 2004; 18 (11): 1835–8.
Choi I, Yoon SR, Park S-Y, Kim H, Jung S-J, Jang YJ, et al. Donor-Derived Natural Killer Cells Infused after Human LeukocyteAntigen– Haploidentical Hematopoietic Cell Transplantation: A Dose-Escalation Study. Biol Blood Marrow Transplant. 2014; 20 (5): 696–704.
Lee DA, Denman CJ, Rondon G, Woodworth G, Chen J, Fisher T, et al. Haploidentical Natural Killer Cells Infused before Allogeneic Stem Cell Transplantation for Myeloid Malignancies: A Phase I Trial. Biol Blood Marrow Transplant. 2016; 22 (7): 1290–8.
Buckley SA, Wood BL, Othus M, Hourigan CS, Ustun C, Linden MA, et al. Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a meta-analysis. Haematologica. 2017; 102 (5): 865–73.
Parkhurst MR, Riley JP, Dudley ME, Rosenberg SA. Adoptive transfer of autologous natural killer cells leads to high levels of circulating natural killer cells but does not mediate tumor regression. Clin Cancer Res Off J Am Assoc Cancer Res. 2011;17 (19): 6287–97.
Anfossi N, André P, Guia S, Falk CS, Roetynck S, Stewart CA, et al. Human NK cell education by inhibitory receptors for MHC class I. Immunity. 2006; 25 (2): 331–42.
Lopez-Vergès S, Milush JM, Schwartz BS, Pando MJ, Jarjoura J, York VA, et al. Expansion of a unique CD57+ NKG2Chi natural killer cell subset during acute human cytomegalovirus infection. Proc Natl Acad Sci U S A. 2011; 108 (36): 14725–32.
Foley B, Cooley S, Verneris MR, Pitt M, Curtsinger J, Luo X, et al. Cytomegalovirus reactivation after allogeneic transplantation promotes a lasting increase in educated NKG2C+ natural killer cells with potent function. Blood. 2012; 119 (11): 2665–74.
Schlums H, Cichocki F, Tesi B, Theorell J, Beziat V, Holmes TD, et al. Cytomegalovirus infection drives adaptive epigenetic diversification of NK cells with altered signaling and effector function. Immunity. 2015; 42 (3): 443–56.
Lee J, Zhang T, Hwang I, Kim A, Nitschke L, Kim M, et al. Epigenetic Modification and Antibody-Dependent Expansion of Memory-like NK Cells in Human Cytomegalovirus-Infected Individuals. Immunity. 2015; 42 (3): 431–42.
Cichocki F, Cooley S, Davis Z, DeFor TE, Schlums H, Zhang B, et al. CD 56dimCD57+NKG2C+ NK cell expansion is associated with reduced leukemia relapse after reduced intensity HCT. Leukemia. 2016; 30 (2): 456–63.
Cooper MA, Elliott JM, Keyel PA, Yang L, Carrero JA, Yokoyama WM. Cytokine-induced memory-like natural killer cells. Proc Natl Acad Sci U S A. 2009 ;106 (6): 1915–9.
Childs RW, Berg M. Bringing natural killer cells to the clinic: ex vivo manipulation. Hematol Am Soc Hematol Educ Program. 2013; 2013: 234–46.
Williams SM, Sumstad D, Kadidlo D, Curtsinger J, Luo X, Miller JS, et al. Clinical scale production of cGMP compliant CD3/CD19 cell depleted NK cells in the evolution of NK cell immunotherapy at a single institution. Transfusion (Paris). 2018; 58(6): 1458–67.
Zhao X, Jiang Q, Jiang H, Hu L, Zhao T, Yu X, et al. Expanded clinical-grade membrane-bound IL-21/4-1BBL NK cell products exhibit activity against acute myeloid leukemia in vivo. Eur J Immunol. 2020; 50 (9): 1374–85.
Grimm EA, Robb RJ, Roth JA, Neckers LM, Lachman LB, Wilson DJ, et al. Lymphokine-activated killer cell phenomenon. III. Evidence that IL-2 is sufficient for direct activation of peripheral blood lymphocytes into lymphokine-activated killer cells. J Exp Med. 1983; 158 (4): 1356–61.
GSK3 Inhibition Drives Maturation of NK Cells and Enhances Their Antitumor Activity | Cancer Research [Internet]. [cited 2021 Dec 15]. Available from: https://cancerresaacrjournals.org.cuml1.md.chula.ac.th/content/77/20/5664.long
Alici E, Sutlu T, Björkstrand B, Gilljam M, Stellan B, Nahi H, et al. Autologous antitumor activity by NK cells expanded from myeloma patients using GMP-compliant components. Blood. 2008; 111 (6): 3155–62.
Miller JS. Therapeutic applications: natural killer cells in the clinic. Hematol Am Soc Hematol Educ Program. 2013; 2013: 247–53.
Srivastava S, Lundqvist A, Childs RW. Natural killer cell immunotherapy for cancer: a new hope. Cytotherapy. 2008; 10 (8): 775–83.
Allan DSJ, Chakraborty M, Waller GC, Hochman MJ, Poolcharoen A, Reger RN, et al. Systematic improvements in lentiviral transduction of primary human natural killer cells undergoing ex vivo expansion. Mol Ther - Methods Clin Dev. 2021; 20:559–71.
Spanholtz J, Preijers F, Tordoir M, Trilsbeek C, Paardekooper J, de Witte T, et al. Clinical-grade generation of active NK cells from cord blood hematopoietic progenitor cells for immunotherapy using a closed-system culture process. PloS One. 2011;6 (6): e20740.
Dolstra H, Roeven MWH, Spanholtz J, Hangalapura BN, Tordoir M, Maas F, et al. Successful Transfer of Umbilical Cord Blood CD34 + Hematopoietic Stem and Progenitorderived NK Cells in Older Acute Myeloid Leukemia Patients. Clin Cancer Res. 2017;23 (15): 4107–18.
Morgan MA, Büning H, Sauer M, Schambach A. Use of Cell and Genome Modification Technologies to Generate Improved “Off-the-Shelf” CAR T and CAR NK Cells. Front Immunol. 2020; 11:1965.
Saetersmoen ML, Hammer Q, Valamehr B, Kaufman DS, Malmberg K-J. Off-the-shelf cell therapy with induced pluripotent stem cell-derived natural killer cells. Semin Immunopathol. 2019; 41 (1): 59–68.
Campana D, Pui CH. Detection of minimal residual disease in acute leukemia: methodologic advances and clinical significance. Blood. 1995; 85 (6): 1416–34.
Rezvani K. Adoptive cell therapy using engineered natural killer cells. Bone Marrow Transplant. 2019; 54 (S2): 785–8.
Bignon J-D, Gagne K. KIR matching in hematopoietic stem cell transplantation. Curr Opin Immunol. 2005; 17 (5): 553–9.
Stringaris K, Marin D, Barrett AJ, Hills R, Sobieski C, Cao K, et al. KIR gene haplotype: an independent predictor of clinical outcome in MDS patients. 2016; 128 (24):5.
Pereira DS, Guevara CI, Jin L, Mbong N, Verlinsky A, Hsu SJ, et al. AGS67E, an Anti-CD37 Monomethyl Auristatin E Antibody-Drug Conjugate as a Potential Therapeutic for B/T-Cell Malignancies and AML: A New Role for CD37 in AML. Mol Cancer Ther. 2015; 14 (7): 1650–60.
Jiang Y-P, Liu BY, Zheng Q, Panuganti S, Chen R, Zhu J, et al. CLT030, a leukemic stem cell-targeting CLL1 antibody-drug conjugate for treatment of acute myeloid leukemia. Blood Adv. 2018; 2 (14): 1738–49.
Kovtun Y, Noordhuis P, Whiteman KR, Watkins K, Jones GE, Harvey L, et al. IMGN779, a Novel CD33- Targeting Antibody-Drug Conjugate with DNA-Alkylating Activity, Exhibits Potent Antitumor Activity in Models of AML. Mol Cancer Ther. 2018; 17 (6): 1271–9.
Chan WK, Kung Sutherland M, Li Y, Zalevsky J, Schell S, Leung W. Antibody-dependent cell-mediated cytotoxicity overcomes NK cell resistance in MLL-rearranged leukemia expressing inhibitory KIR ligands but not activating ligands. Clin Cancer Res. 2012; 18 (22): 6296-305.
Le Roy A, Prébet T, Castellano R, Goubard A, Riccardi F, Fauriat C, Granjeaud S, Benyamine A, Castanier C, Orlanducci F, Ben Amara A, Pont F, Fournié JJ, Collette Y, Mege JL, Vey N, Olive D. Immunomodulatory Drugs Exert Anti-Leukemia Effects in Acute Myeloid Leukemia by Direct and Immunostimulatory Activities. Front Immunol. 2018; 9: 977.
Cooley S, He F, Bachanova V, Vercellotti GM, DeFor TE, Curtsinger JM, et al. First-in-human trial of rhIL- 15 and haploidentical natural killer cell therapy for advanced acute myeloid leukemia. Blood Adv. 2019; 3 (13): 1970–80.
Nguyen R, Wu H, Pounds S, Inaba H, Ribeiro RC, Cullins D, et al. A phase II clinical trial of adoptive transfer of haploidentical natural killer cells for consolidation therapy of pediatric acute myeloid leukemia. J Immunother Cancer. 2019; 7(1):81.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Greater Mekong Sub-region Medical Journal
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
